Summary.-The effects of adoptive transfer of spleen cells from tumour-bearing mice on the growth of Moloney murine sarcoma virus (M-MuSV)-induced primary tumours in BALB/c mice were studied. The effects were in 2 directions, depending on the time of lymphocyte inoculation; when spleen cells from tumour-bearing mice 12 days after M-MuSV inoculation were inoculated into recipient mice before M-MuSV inoculation, the appearance of tumours was significantly delayed and their incidence was reduced, whereas when these lymphocytes were inoculated after the development of tumours in recipient mice, tumour growth was significantly enhanced. The data indicated that these inhibiting and enhancing effects were mediated mainly by T cells. The mechanisms of the paradoxical effects were investigated.
MANY investigators in tumour immunology have reported that tumours possess specific antigens which are recognized by, and induce an immune response in the host, as detected in a variety of in vitro systems. However, despite these immune responses observed in vitro, most tumours grow progressively to kill the host animal. Hypotheses which have been proposed to explain the discrepancies between in vitro and in vivo results include; (i) the presence of specific serum blocking factors in tumour-bearing mice (Hellstrom and Hellstrom, 1969; Hellstrom and Hellstrom, 1970; Sjogren and HellstrOm, 1971; Jurin and Suit, 1974; Kilburn et al., 1976; McMaster et at., 1977);  (ii) suppressor-cell activity against specific immune lymphocytes (Glaser et at., 1975; Fujimoto et al., 1976a Fujimoto et al., , 1976b or non-specific lymphocytes (Kirchner et al., 1974; Gorczynski, 1974; Kirchner et al., 1975) ; and (iii) cell-mediated enhancement of tumour growth (Ilfeld et al., 1973; Umiel and Trainin, 1974; Small and Trainin, 1976; Gabizon et al., 1976) .
To analyse further the possibilities mentioned above, it is necessary to develop experimental systems which permit the direct investigation of the in vivo effects of immune lymphocytes on tumour growth in a form as close as possible to the naturally occurring disease. Our experiments attempted to approximate to such a system, and involved adoptive transfer of lymphocytes to mice bearing Moloneymurine sarcoma virus (M-MuSV)-induced primary tumours and observation of the resulting modulation in the pattern of tumour growth. The advantages of using the M-MuSV-induced primary tumour system in studying adoptive lymphocyte transfer were:
(i) by selecting the conditions, we could produce sarcomas in animals with growing patterns suited to the purpose of a particular experiment;
(ii) we could study the effect of immune response not only on the growth of tumours but also on the appearance of tumours, following viral carcinogenesis, which cannot be studied by using already malignantly transformed transplanted tumours; (iii) in virus-induced primary tumours (which, contrary to chemically induced primary tumours, share tumour-specific antigens) we could investigate the effects of lymphocytes from one animal on the growth of primary tumours in other animals;
(iv) we could compare our in vivo results with those in the literature on in vitro experiments with M-MuSV-induced tumours; and (v) an autochthonous system, such as the M-MuSV-induced primary tumours we selected, is a closer model to human malignancies than a syngeneic transplanted tumour system.
In the present study, we observed two mutually antagonistic effects of lymphocytes from tumour-bearing mice on MMuSV-induced tumours. That is, when we inoculated these lymphocytes into mice before the virus inoculation, appearance of tumours was delayed, and their incidence was reduced (inhibiting effect). However, when we inoculated these lymphocytes into mice which had already developed tumours, they enhanced tumour growth (enhancing effect). We investigated the nature of the effective cell population as well as the kinetics of these paradoxical effects.
MATERIALS AND METHODS
Mice.-Female BALB/c mice were obtained from the Mammalian Genetics and Animal Production Section, National Cancer Institute, Bethesda, Maryland.
Induction of sarcomas-.One-tenth ml of 107 focus-forming units (FFU)/ml M-MuSV (No. 244, the gift of Dr A. F. Gazdar, NCI) at 1: 20 dilution was inoculated i.m. into the hind leg of 7-to 9-week-old mice to produce tumours as shown in Fig. 1 Neutralization test.-Appropriate concentrations of virus in 0-4 ml of medium were mixed with 0 4 ml of 1: 8 diluted test serum. The mixture was incubated at room temperature for 60 min and then at 4°C for 30 min with periodical shaking. A volume of 0-2 ml of this mixture was then added to a plate in which D-56 cells had been seeded on the previous day and treated with DEAEDextran before the test. The focus-forming activity of the remaining virus was determined 6 days after incubation. The ratio (V/Vo) was the surviving fraction of virus.
RESULTS

Typical growth patterns of M-MuS Vinduced primary sarcomas
As has been stated elsewhere (Kirchner et Fig. 2 ). When the virus was inoculated into adult mice (7-9 weeks old) tumours regressed more conspicuously after the first peak, then stayed the same size for 2 weeks, until they started to grow again around Day 35. The stages of this slowgrowing tumour system may be desig- Fig. 2 ). In the following study, unless otherwise stated, the same lot of virus preparation (progressor) and 7-to 9-weekold mice were used for the observation of tumour growth, and 5-to 6-week-old mice were used as the source of spleen cells. tumour growth. For the inhibiting experiment, 50 5-week-old mice were separated into 5 groups. One week before M-MuSV inoculation, each group was inoculated i.p. with 1 X 106-5 x 107 12S lymphocytes or with medium only (Fig. 5A) When the 12S lymphocytes were treated with anti-6 antibody and complement, the results were consistent with those obtained with cells separated on nylon-wool columns. The T-cell-depleted population exerted a smaller effect in both enhancing and inhibiting experiments than 12S lymphocytes treated with complement alone (data not shown).
Effect of 12S lymphocytes on antigenically distinct tumour cells
To see whether the effects of lymphocytes were specific or non-specific, these experimental systems were applied to an antigenically distinct transplanted tumour. Neither enhancement nor inhibition of the growth of methylcholanthrene-induced BALB/c fibrosarcoma (MCA-15B) was observed with 12S lymphocytes (Fig. 7) . 
Infectious centre assoay of 128 lymiphocytes
The possibility of virus infection in 128 lymphocytes was examined by the infectious-centre assay. As shown in Table I (Kudo et al., 1974) , washed x4 in phosphate-buffered saline (PBS) and inoculated T Group which received M-MuSV inoculation 1 week after 12S inoculation.
i.p. into tumour-bearing or normal mice, neither enhancement nor inhibition was observed (data not shown).
Neutralization test
Neutralization tests were performed to detect neutralizing antibody against MMuSV in serum of mice inoculated with 12S lymphocytes. Ten mice received 12S or NS lymphocytes (2 x106 cells/mouse), and 5 mice in each group were inoculated i.m. with M-MuSV a week after the lymphocyte inoculation. Serum from mice receiving 12S lymphocytes demonstrated earlier neutralizing-antibody activity than that from mice receiving NS lymphocytes (Table II) .
DISCUSSION
The data presented in this paper clearly demonstrate the existence of lymphocyte population(s) in mice with M-MuSVinduced primary tumours, which either enhanced or inhibited tumour growth, depending on the stages of tumour growth at which the lymphocytes were transferred. If lymphocytes collected 12 days after M-MuSV inoculation (designated 12S in our experiments) were inoculated before virus inoculation, tumour appearance was delayed and tumour incidence was reduced (inhibiting effect). If the same lymphocytes were inoculated after the development of sarcomas, especially early in tumour growth, significant enhancement of tumour growth was observed (enhancing effect). Furthermore, the results indicate that these effects were mediated mainly by the nylon-wool non-adherent, 0-bearing T-cell population.
Why did the same subpopulation of lymphocytes manifest opposite activities when they were inoculated at different stages of tumour growth? Our results may be attributed to a discrepancy between the activity of lymphocytes in vivo and in vitro. If lymphocytes with tumour-enhancing activity were converted to tumour-inhibiting lymphocytes after their transfer into a recipient animal, inhibition of tumour growth would be observed when the virus was inoculated after the conversion. In vitro evidence suggests that spleen cells 12 days after M-MuSV inoculation are in the eclipse stage, as demonstrated by decreased cytotoxic activity against syngeneic MMuSV-or M-MuLV-induced tumour cells (Hellstrom and Hellstrom, 1969; Kirchner et al., 1974) . Two weeks after this stage, however, the lymphocytes regain their cytotoxic activity, suggesting a conversion of lymphocyte activity. Another possibility is that the particular expression of lymphocyte activity depends on the condition of the host animals. In contrast to transplanted tumours, the M-MuSV- Another relevant question is whether these enhancing and inhibiting effects are mediated by a single subpopulation of T lymphocytes. Spleen cells from tumourbearing mice can be fractionated by means of velocity sedimentation into subpopulations capable of inhibiting or enhancing tumour growth . It is conceivable that 2 lymphocyte subpopulations with conflicting activities coexist in the 12S lymphocytes, and that either one of these activities is expressed under certain conditions of the host animals.
The effect of 12S lymphocytes from M-MuSV-induced sarcoma-bearing mice was compared to that of antigenically distinct tumour cells (MCA-15B). Neither enhancement nor inhibition of tumour was observed with MCA-15B cells. These results, as well as the presence of neutralizing antibody against M-MuSV in the serum of mice inoculated with 12S lymphocytes, suggest some specificity in our findings. Because of the lack of a suitable control for the sarcoma virus, however, we could not study the effect of 12S lymphocytes against other primary tumour systems. Therefore the question whether the effect of 12S lymphocytes is specific to the M-MuSV-induced tumour system or is shared by other primary tumours is still open.
We conclude that the inhibiting effect of 128 lymphocytes was not due to the presence of virus in the 12S lymphocytes because, firstly, virus infection of these lymphocytes was too low to induce such an effect (whereas 104 FFU of virus was required to show significant inhibition, only 106 lymphocytes, which released no more than 40 FFU of virus, manifested significant inhibition). Secondly, the Tcell-rich population, which was probably the main effector population that produced the inhibiting effect, released a lower amount of virus than the B-cell-rich population, according to the infectiouscentre assay. Finally, preliminary experiments showed that when 12S lymphocytes (releasing 10-40 FFU of virus/I x 106 cells) were irradiated, they failed to inhibit the appearance of tumours. The earlier appearance of virus-neutralizing antibody in mice inoculated with 12S lymphocytes suggests the participation of antibody formation in the inhibiting effect. Production of cytotoxic T lymphocytes specific to sarcoma cells may also be involved.
In the experiments into the mechanisms of tumour-growth enhancement, the effect of 12S lymphocytes was: (a) observable at the first progressive stage of tumour growth (Fig. 4A) ; (b) approximately proportional to the numbers of inoculated lymphocytes (Fig. 5B) ; (c) mediated mainly by the T-cell population (Fig. 6B) ; and (d) not observed against MCA-15B cells (Fig. 7B ). Taking these results into consideration, possible explanations for the mechanisms of enhancement included in our discussion are: (i) non-specific tumour enhancement, (ii) suppressor-cell activity, and (iii) formation of blocking factor.
(i) Non-specific tumour enhancement
This has been demonstrated in transplanted tumour systems (Ilfeld et al., 1973; Umiel and Trainin, 1974; Small and Trainin, 1976; Gabizon et al., 1976) . Although the failure to enhance antigenically distinct syngeneic tumour cells (MCA-15B) may imply that the mechanism of enhancement in our system is a specific one, it is possible that this failure resulted from the nature of the tumour cells. These cells were growing progressively, and hence might have concealed an enhancing effect. Actually, in some experiments with fast-growing M-MuSV-induced tumours in young mice, we failed to show an enhancing effect on tumour growth. It is unlikely, however, that a cell-free factor released by 12S lymphocytes enhanced 562,) GROWTH MODIFICATION OF VIRAL TUMOURS tumour growth, because culture medium, collected from 1 2S lymphocytes and highly concentrated, showed no enhancing effect (unpublished observation).
Although the existence of a lymphocyte population which inhibits tumour growth in vivo has not yet been reported (Ilfeld et al., 1973; Nordlund and Gershon, 1975) , in vitro evidence suggests the presence of cytotoxic T cells and cytostatic B cells in the M-MuSV system (Hellstrom and Hellstr6m, 1969; Herberman et al., 1974; Lamon et al., 1972; Plata et al., 1974; Leclerc et al., 1972; Lamon et al., 1974; Plata et al., 1976) and the regression of tumours induced by regressor M-MuSV has been attributed to the immune response of the host animals (Fefer et al., 1968; Weinert et al., 1974) . In our experiments with progressor M-MuSV, the regressive stage and the first plateau stage observed in adult mice, as well as the occasional regression of tumours, may also be ascribed to the results of a host immune response.
(ii) Suppressor-cell activity Specific suppressor-cell activity of lymphocytes from tumour-bearing animals has been reported in transplanted-tumour systems (Fujimoto et al., 1976a, b) . In the M-MuSV system, suppressor-cell activity of tumour-bearing spleen cells has been reported in in vitro stimulation of lymphocytes (Kirchner et al., 1974; Gorczynski, 1974; Kirchner et al., 1975) . In our system, enhancement of tumour growth could possibly be mediated by suppressor cells. Afferent suppression of immune response (inhibiting the production of cytotoxic or antibody-forming lymphocytes) does not seem to explain the enhancing effect of 128 lymphocytes, because these cells, when inoculated before virus injection, demonstrated an inhibiting effect. However, it is possible that 1 2S lymphocytes do not suppress antibody formation against the sarcoma virus, but, instead, suppress the production of cytotoxic lymphocytes. Another possibility is that if 2 lymphocyte subpopulations with conflicting activities co-exist in the 12S lymphocytes (cytotoxic killer cells and suppressor cells) suppressor cells may lose their activity in the absence of antigen stimulation (Fujimoto et al., 1976b; Basten et al., 1975 (iii) Formation of blocking factor
The induction of blocking factor by the administration of 12S lymphocytes cannot be excluded as a possibility. Enhanced antibody formation induced by the inoculation of 12S lymphocytes may account for their enhancing activity. It is also possible that antibody against 12S lymphocytes, elicited by their inoculation, blocked the specific immune response against tumour cells. Anti-idiotypic antibody formation has been reported in the enhancement of renal allografts in rats (McKearn et al., 1974; Stuart et al., 1976a Stuart et al., , 1976b . Our preliminary experiments indicated that X-irradiated 12S lymphocytes similarly enhanced tumour growth in the M-MuSV system. This finding suggests that the lymphocytes which mediated the enhancing effect were radiation-resistant, or that they served as an antigen to elicit 1563 anti-idiotypic antibody in enhancing mechanisms.
Whatever the mechanisms of the enhancing effect of 12S lymphocytes, their elucidation will bring about a better understanding of the reason why tumours grow progressively in vivo in spite of the in vitro evidence of immune response to the tumour cells.
